This report outlines the threat of pharmaceutical crime in the EU and beyond, as assessed by Europol. It aims to raise awareness of the ways criminal networks exploit consumers and industry in generating illegal revenue through producing and selling counterfeit medicines.

Cervical cancer, primarily caused by persistent Human Papillomavirus (HPV) infection, remains one of the leading causes of cancer-related deaths among women in developing countries. Although HPV vaccines are widely available in these regions, vaccine uptake remains persistently low. To address...

Background Evidence on the cost effectiveness of deprescribing in multimorbidity is limited. Objective To investigate the cost effectiveness of a general practitioner (GP) delivered, individualised medication review to reduce polypharmacy and potentially inappropriate prescribing in older...

Objectives The aim of this study is to analyse the trends in technology appraisals for non-small cell lung cancer (NSCLC) treatments performed by the National Institute for Health and Care Excellence (NICE) over the last ten years. Methods A systematic search was conducted for single technology...

In December 2020, Germany implemented a policy restricting online pharmacies from offering rebates on prescription drugs to members of the statutory health insurance. This policy change created a natural experiment, allowing us to analyze its impact on the pharmaceutical market using...

This Research Paper addresses the growing problem of access to essential medicines, focusing on the role of intellectual property rights, particularly patent rights, in restricting access by enabling pharmaceutical market monopolies that keep drug prices high. The paper explores the Bolar...

Background In their interesting systematic review, Gallehzan et al. quoted our article Cost-utility analysis of teriflunomide in naïve vs. previously treated patients with relapsing-remitting multiple sclerosis (RRMS) in Italy. While we are grateful to Gallehzan et al. for their interest in the...

Community pharmacies deliver high-quality health care and are responsible for medication safety. The goal of the government is to ensure nationwide, accessible, and affordable medical health-care services provided by pharmacies. Therefore, the per capita density of community pharmacies matters....

The 340B Drug Pricing Program was instituted to bolster the health care safety net without relying on taxpayer money. It allows participating health care facilities - most of which are hospitals - to purchase drugs filled at in-house or contracted external pharmacies at discounts from...

I study the passthrough of regulated ad valorem pharmacy markups and reduced Value Added Tax (VAT) rates to pharmaceutical retail prices in Finland. My reduced form evidence shows that pharmaceutical manufacturers respond to a decrease in regulated pharmacy markups by increasing their wholesale...

Patients in rural areas have higher rates of opioid use and overdose than those in urban areas that are linked to the greater prevalence and amounts of opioids prescribed. We merge individual claims data with county-level supply and demand factors to examine this relationship between...

Background: The supply chain refers to the full process of creating and providing a good or service, starting with the raw materials and ending with the final customer. It requires cooperation and coordination between many parties, including the suppliers, manufacturers, distributors, retailers,...

Purpose: This study extends previous research by exploring the key lessons learned by the pharmaceutical industry in South Africa from the COVID-19 pandemic supply chain disruptions. Design/methodology/approach: Having embraced the interpretivist paradigm, 25 supply chain professionals were...

In recent years, concerns about transactions in the pharmaceutical sector harming innovation and competition through the discontinuation of overlapping drug R&D projects, so-called "killer acquisitions", have prompted regulatory action and research. The objective of this study is twofold. First,...

The Regulation on Health Technology Assessment (Regulation (EU) 2021/2282) HTAR establishes a framework for conducting Joint Clinical Assessments (JCA) at EU level. These assessments support member states in their national Health Technology Assessment (HTA) processes, providing a scientific...

The Regulation on Health Technology Assessment (Regulation (EU) 2021/2282) HTAR establishes a framework for conducting Joint Clinical Assessments (JCA) at EU level. These assessments support member states in their national Health Technology Assessment (HTA) processes, providing a scientific...

The COVID-19 vaccines played a pivotal role in safeguarding populations. Yet, vaccine hesitancy remained a significant barrier to increasing coverage rates, as many high-income countries faced prolonged vaccine refusal campaigns. In Japan, vaccine doses were administered under a reservation...

The rising number of refugees and internally displaced people (IDPs) presents new challenges for vaccine distribution and the spread of diseases. How do forcibly displaced population inflows affect infectious diseases incidence in host communities? Can a policy intervention that vaccinates...

This study investigates the relationship between economic preferences and COVID-19 vaccination readiness using two representative samples of the German population (N 5,000). We elicited altruism, patience, risk-taking and trust using validated survey questions. We find robust, positive...

This Critical Medicines Alliance is a new consultative mechanism bringing together national authorities, industry, civil society, the Commission and EU agencies to identify the best measures to address and avoid shortages of critical medicines. It complements regulatory measures in the proposed...